| Title |
New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma
|
|---|---|
| Published in |
Journal of Cancer Research and Clinical Oncology, October 2012
|
| DOI | 10.1007/s00432-012-1331-y |
| Pubmed ID | |
| Authors |
Ilknur Kozanoglu, Melis Kartal Yandim, Zeynep Birsu Cincin, Hakan Ozdogu, Bedia Cakmakoglu, Yusuf Baran |
| Abstract |
Propranolol, a non-selective β-adrenergic receptor blocker, has been used for the treatment of the patients with hypertension for more than 50 years. There are several in vitro and in vivo evidences that β-adrenergic receptor antagonists inhibit proliferation and angiogenesis and also increase apoptosis in breast, skin, and colon cancers. The aim of this study was to investigate the cytotoxic and apoptotic effects of propranolol and the genes involved in propranolol-induced apoptosis in multiple myeloma cells. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 3% |
| Unknown | 31 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 22% |
| Researcher | 5 | 16% |
| Student > Bachelor | 4 | 13% |
| Student > Ph. D. Student | 3 | 9% |
| Other | 3 | 9% |
| Other | 3 | 9% |
| Unknown | 7 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 38% |
| Biochemistry, Genetics and Molecular Biology | 3 | 9% |
| Agricultural and Biological Sciences | 3 | 9% |
| Chemistry | 3 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 6 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 October 2012.
All research outputs
#20,664,599
of 25,393,455 outputs
Outputs from Journal of Cancer Research and Clinical Oncology
#1,970
of 2,825 outputs
Outputs of similar age
#151,049
of 193,844 outputs
Outputs of similar age from Journal of Cancer Research and Clinical Oncology
#19
of 21 outputs
Altmetric has tracked 25,393,455 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,825 research outputs from this source. They receive a mean Attention Score of 3.8. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 193,844 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.